Showing results (1-10 of 39) with videos related to
Sort By:
Pageof 4
Medicines (Basel, Switzerland)|September 21, 2017
The Changing Landscape of Breast Cancer: How Biology Drives TherapySarah Friend, Melanie RoyceCancer Treatment Reviews|August 10, 2018
Everolimus-based combination therapies for HR+, HER2- metastatic breast cancerJoyce O'Shaughnessy, J Thaddeus Beck, Melanie RoyceInternational Journal of Medical Sciences|November 13, 2008
XeNA: capecitabine plus docetaxel, with or without trastuzumab, as preoperative therapy for early breast cancerStefan Glück, Edward F McKenna, Melanie RoyceOncology (Williston Park, N.Y.)|May 21, 2014
HER2-targeted therapy for early-stage breast cancer: a comprehensive reviewUrsa Brown-Glaberman, Zoneddy Dayao, Melanie RoyceOncology (Williston Park, N.Y.)|October 10, 2006
Disparities in cancer care among racial and ethnic minoritiesBethany Kolb, Anne Marie Wallace, Deidre Hill, et al.Plos One|October 25, 2019
Temporal trends in breast cancer survival by race and ethnicity: A population-based cohort studyDeirdre A Hill, Eric R Prossnitz, Melanie Royce, et al.Medical Oncology (Northwood, London, England)|September 5, 2014
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapySoley Bayraktar, Melanie Royce, Lisette Stork-Sloots, et al.BMC Cancer|July 21, 2012
Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancerHugo Arias-Pulido, Nabila Chaher, Yun Gong, et al.Breast Cancer Research and Treatment|May 17, 2012
Early breast cancer with positive margins: excellent local control with an upfront brachytherapy boostThomas M Schroeder, Ben Liem, Sagus Sampath, et al.Breast Cancer Research and Treatment|August 22, 2017
Estrogen receptor quantitative measures and breast cancer survivalDeirdre A Hill, Marc Barry, Charles Wiggins, et al.Pageof 4